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Methods
Background
This work aims to assess whether increasing time between diagnosis/first doctor visit
and surgery for early stage non-small cell lung cancer (NSCLC) is associated with
poorer survival.
Lung cancer is the second most common cancer in both men and women, and
comprise 13% of all new cancers. It is by far the leading cause of cancer death among
men and women. Each year, more people die of lung cancer than of colon, breast, and
prostate cancers combined.(1,2) There is an increasing effort towards early detection of
lung cancer, since it is a curable cancer if diagnosis and treatment are performed in a
timely manner.(3)
Surgical resection is the most effective treatment for lung cancer in early stages,
providing greater long-term survival. Clinical guidelines on acceptable time frames
between diagnosis and resection of early-stage lung cancer do not exist.
Greater intervals between diagnosis of early-stage NSCLC and surgery are
associated with worse survival. Efforts to minimize delays, particularly factors that
prolong the period from diagnosis to first contact with a lung cancer provider may
improve survival.
We identified a retrospective cohort of incident lung cancer cases who had surgical
treatment for lung cancer at our institution between January 2009 and December 2017,
and no prior radiation or chemotherapy. We assessed overall survival (OS) and
predictors included a) time from first contact to surgery; and b) time from diagnosis to
surgery. The association between date of diagnosis and date of first contact of a health
care provider to surgery, and survival for patients with early stage NSCLC was
assessed using multivariable Cox proportional hazard. We investigated four cut-off
points: surgery within 15 days, 30 days, 60 days and 90 days. We controlled for socio-
demographic characteristics as well as clinical outcomes.
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Table 1. Characteristics of the study cohort of lung 
cancer patients registered in the UMass Memorial Health 
Care from 2009 to 2017.
Figure 1. Relationship between timing to surgery and overall 
survival for patients with clinical stage I and II NSCLC. 
Adjusted Cox models for the four cut off points of time to 
surgery (A) 15 days; (B) 30 days, (C) 60 days and (D) 90 
days. Median values for all covariates are used as reference 
standard. 
Results
Figure 1. Diagram showing schema of study 
subject selection. NSCLC, early stage.
Surgery was performed more than 60 days of diagnosis 
in 115 (25.7%) patients, their OS was significantly 
worse than patients who had surgery earlier (HR=1.7 
[95% CI: 1.1-2.6]).
Model was adjusted for age, gender; race; ethnicity ; education 
level; income level; smoking status ; Charlson comorbidities 
score; health insurance type; type of resection; histology; 
primary site of lesion; regional nodes examined  node positivity; 
laterality; radiation (post-surgery); chemotherapy (post-surgery); 
TNM pathological staging group categories; specialty seen in the 
first contact; 
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Our cohort comprised 451 patients. The
age average was 67 years, 61% female,
94.7% white, and 9% never smoked.
Clinical Stage 1A and 1B corresponded to
86.5% of patients while in pathological
stage it was 76%.
Table 2. Cox proportional hazard model
We did not find any significant association between OS and (a) the time from first visit to
surgery for either, any provider or thoracic surgery.
The time from diagnosis to surgery (b) was associated with OS and the threshold time
associated with statistically significant worse survival was 60 days after diagnosis.
The 5-year overall survival was 56.0%.
Surgery occurred a median 40 days
after the diagnosis and 43 days after
the first visit and within 35 days if the
first appointment was with a thoracic
surgeon.
(D)
(B)
(C)
(A)
Total (N) 451
N %
Age [Mean(SD)] 67 0.4
Gender Female 276 61.20%
Ethnicity  White 427 94.70%
Black 12 2.70%
Hispanic Origin Yes 13 3%
High Education Yes 178 39%
High Income level Yes 13 3%
Smoking status
Current smoker (cigarette, 
cigar/pipe)
175 39%
Never used 41 9%
Previous use 234 52%
Charlson Comorbidities Score 0 339 75%
1 to 3  105 23%
4 to 6 7 2%
Health Insurance Medicaid 51 11%
Medicare 270 60%
HMO_PPO 117 26%
Non‐specified 13 3%
Type of Resection Lobectomy 227 50%
Pneumonectomy 33 7%
Segmentectomy 6 1%
Wedge 185 41%
Histology adenocarcinoma 336 75%
squamous cell carcinoma 101 22%
Others 14 4%
Primary Site of Lesion Lower Lobe 151 33%
Middle Lobe 20 4%
Upper Lobe 274 61%
Regional Nodes Examined [Mean(SD)] 9.3 (0.4) 
Regional Nodes Examined  Yes 356 79%
Any regional Node positive Yes 50 11%
Laterality Right 270 60%
Left 180 40%
Radiation (post‐surgery) Yes 27 6%
Chemotherapy (post‐surgery) Yes 78 17%
 TNM Pathological staging group categories Stage 1 33 7%
Stage 1A 185 41%
Stage 1B 111 25%
Stage 2, 2A e 2B 38 8%
Stage 3A, 3B and 4 38 8%
Specialty seen in the first contact Thoracic 272 64%
Oncology 34 8%
Pulmonary 97 23%
PCP 15 4%
Others 5 1%
Variables in the final model  HR  95% CI  p‐value 
Male vs female  1.8  1.3  2.6  0.00 
Late stage vs early stage  3.8  2.2  6.5  0.00 
Non‐white vs white   5.6  1.4  23.1  0.02 
Sub‐lobar resection vs Lobectomy   1.9  1.3  2.8  0.00 
Medicare/Medicaid vs non‐Medicare  1.6  1.0  2.5  0.05 
Time from surgery greater than 60 days vs less than 60 days  1.7  1.1  2.6  0.01 
 
